ATE555102T1 - N-acylsphingosinglucosyltransferase-inhibitor - Google Patents

N-acylsphingosinglucosyltransferase-inhibitor

Info

Publication number
ATE555102T1
ATE555102T1 AT09003291T AT09003291T ATE555102T1 AT E555102 T1 ATE555102 T1 AT E555102T1 AT 09003291 T AT09003291 T AT 09003291T AT 09003291 T AT09003291 T AT 09003291T AT E555102 T1 ATE555102 T1 AT E555102T1
Authority
AT
Austria
Prior art keywords
acylsphingosine
lucosyltransferase
inhibitor
disclosed
synthesis
Prior art date
Application number
AT09003291T
Other languages
English (en)
Inventor
Bradford Hirth
Craig Siegel
James Shayman
Carol Nelson
David Harris
Diane Copeland
Original Assignee
Genzyme Corp
Univ Michigan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23182463&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE555102(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genzyme Corp, Univ Michigan filed Critical Genzyme Corp
Application granted granted Critical
Publication of ATE555102T1 publication Critical patent/ATE555102T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Cosmetics (AREA)
  • Peptides Or Proteins (AREA)
AT09003291T 2001-07-16 2002-07-16 N-acylsphingosinglucosyltransferase-inhibitor ATE555102T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US30581401P 2001-07-16 2001-07-16

Publications (1)

Publication Number Publication Date
ATE555102T1 true ATE555102T1 (de) 2012-05-15

Family

ID=23182463

Family Applications (2)

Application Number Title Priority Date Filing Date
AT09003291T ATE555102T1 (de) 2001-07-16 2002-07-16 N-acylsphingosinglucosyltransferase-inhibitor
AT02750099T ATE554082T1 (de) 2001-07-16 2002-07-16 N-acetylsphingosin glukosyltransferase inhibitor

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT02750099T ATE554082T1 (de) 2001-07-16 2002-07-16 N-acetylsphingosin glukosyltransferase inhibitor

Country Status (15)

Country Link
US (11) US6855830B2 (de)
EP (3) EP2266968B1 (de)
JP (6) JP5038582B2 (de)
AT (2) ATE555102T1 (de)
BE (1) BE2015C029I2 (de)
BR (3) BR122015016313B8 (de)
CA (1) CA2453978C (de)
CY (1) CY2015028I1 (de)
DK (3) DK2067775T3 (de)
ES (3) ES2399323T3 (de)
FR (1) FR15C0036I2 (de)
IL (3) IL159905A0 (de)
LU (1) LU92717I2 (de)
PT (3) PT2266968E (de)
WO (1) WO2003008399A1 (de)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1384719A1 (de) * 1999-07-09 2004-01-28 The Regents of The University of Michigan Inhibitoren des Glykosylzeramidsynthase-Enzyms für die Behandlung von Krebs, Sphingolipidosis und mikrobiellen Infektionen
MY164523A (en) * 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
CA2434028C (en) 2001-01-10 2010-11-09 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
US7723296B2 (en) 2001-01-18 2010-05-25 Genzyme Corporation Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof
EP2266968B1 (de) 2001-07-16 2013-01-09 Genzyme Corporation Synthese von UDP-Glukose: N-Acetylsphingosin Glikosyltransferase Inhibitoren
AU2002348261A1 (en) * 2001-11-26 2003-06-10 Genzyme Corporation Diastereoselective synthesis of udp-glucose : n-acylsphingosine glucosyltransferase inhibitors
US20060217560A1 (en) * 2002-04-29 2006-09-28 Shayman James A Amino ceramide-like compounds and therapeutic methods of use
US6916802B2 (en) * 2002-04-29 2005-07-12 Genzyme Corporation Amino ceramide-like compounds and therapeutic methods of use
JP4195411B2 (ja) * 2004-04-12 2008-12-10 セイコーエプソン株式会社 有機エレクトロルミネッセンス装置の製造方法
CA2586761A1 (en) * 2004-11-10 2006-05-18 Genzyme Corporation Methods of treating diabetes mellitus
CN101151248B (zh) 2005-01-26 2012-06-20 阿勒根公司 具有镇痛活性和/或免疫刺激物活性的3-芳基-3-羟基-2-氨基丙酸酰胺类、3-杂芳基-3-羟基-2-氨基丙酸酰胺类以及相关化合物
EP2032134B1 (de) * 2006-05-09 2015-06-24 Genzyme Corporation Verfahren zur behandlung von krankhafter fettleber durch hemmung der glucosphingolipid-synthese
CA2675968C (en) 2007-01-18 2019-05-21 Genzyme Corporation Oligosaccharides comprising an aminooxy group and conjugates thereof
US8173683B2 (en) 2007-03-06 2012-05-08 Allergan, Inc. Methods for treating cognitive disorders
US20140179925A1 (en) 2009-09-04 2014-06-26 Allergan, Inc. Methods for treating cognitive disorders using 3-aryl-3-hydroxy-2-amino-propionic acid amides, 3-heteroaryl-3-hydroxy-2-amino-propionic acid amides and related compounds
PT2481407T (pt) 2007-03-06 2018-12-28 Allergan Inc Compostos para utilização no tratamento de distúrbios cognitivos
US9314466B2 (en) 2007-03-06 2016-04-19 Allergan, Inc. Methods for treating cognitive disorders using 1-benzyl-1-hydroxy-2,3-diamino-propyl amines, 3-benzyl-3-hydroxy-2-amino-propionic acid amides and related compounds
US8304447B2 (en) * 2007-05-31 2012-11-06 Genzyme Corporation 2-acylaminopropoanol-type glucosylceramide synthase inhibitors
KR20160085917A (ko) 2007-10-05 2016-07-18 젠자임 코포레이션 세라마이드 유도체로 다낭성 신장질환을 치료하는 방법
US8168631B2 (en) 2008-02-05 2012-05-01 Allergan, Inc. 3-(4-fluorophenyl)-3-hydroxy-2-amino-propionic acid amides and related compounds having analgesic activity
WO2010014554A1 (en) 2008-07-28 2010-02-04 Genzyme Corporation Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease
US8309593B2 (en) 2008-10-03 2012-11-13 Genzyme Corporation 2-acylaminopropoanol-type glucosylceramide synthase inhibitors
SI2889043T1 (sl) 2008-12-16 2019-08-30 Genzyme Corporation Sintetične vmesne spojine za pripravo konjugatov oligosaharid-protein
PL3133070T3 (pl) 2009-11-27 2020-01-31 Genzyme Corporation Eliglustat (Genz 112638) jako inhibitor syntazy glukozyloceramidowej do zastosowania w sposobie leczenia choroby Fabry’ego lub choroby Gauchera, przy czym sposób obejmuje dostosowanie indywidualnej dawki terapeutycznej do metabolizmu P450 u pacjenta
JP5467146B2 (ja) 2010-04-16 2014-04-09 京セラ株式会社 無線通信システム、高電力基地局、低電力基地局、及び通信制御方法
EP2699676A1 (de) 2011-04-22 2014-02-26 Genzyme Corporation Modifizierte saure alpha-glukosidase mit beschleunigter verarbeitung
US8961959B2 (en) 2011-10-17 2015-02-24 The Regents Of The University Of Michigan Glucosylceramide synthase inhibitors and therapeutic methods using the same
WO2014150043A1 (en) 2013-03-15 2014-09-25 Concert Pharmaceuticals Inc. Inhibitors of the enzyme udp-glucose: n-acyl-sphingosine glucosyltransferase
TWI690511B (zh) 2013-09-20 2020-04-11 美商拜奧馬林製藥公司 用於治療疾病之葡萄糖苷基腦醯胺（ｇｌｕｃｏｓｙｌｃｅｒａｍｉｄｅ）合成酶抑制劑
WO2015059679A1 (en) * 2013-10-25 2015-04-30 Dr. Reddy's Laboratories Limited Improved process for the preparation of eliglustat
MX376685B (es) 2013-10-29 2025-03-07 Biomarin Pharm Inc Derivados de n-(1-hidroxi-3-(pirrolidinil)propan-2-il)pirrolidin-3-carboxamida como inhibidores de glucosilceramida sintasa.
US10202340B2 (en) 2015-02-02 2019-02-12 The Regents Of The University Of Michigan Glucosylceramide synthase inhibitors and therapeutic methods using the same
CN104557851B (zh) * 2015-02-10 2017-04-05 苏州明锐医药科技有限公司 依鲁司他的制备方法
WO2016166170A1 (en) 2015-04-14 2016-10-20 Sandoz Ag Crystalline eliglustat hydrochloride
WO2017068496A1 (en) * 2015-10-20 2017-04-27 Dr. Reddy' S Laboratories Limited Improved process for the preparation of eliglustat and its salts
CN105646442A (zh) * 2015-10-27 2016-06-08 北京凯莱天成医药科技有限公司 一种依利格鲁司他的制备方法
WO2017178499A1 (en) 2016-04-11 2017-10-19 Spedding Research Solutions Inhibitors of glucosylceramide degradation in the treatment of diseases of the motor units
CN106349210A (zh) * 2016-08-24 2017-01-25 北京阳光诺和药物研究有限公司 一种制备酒石酸艾力骨司坦的方法
CN106967042B (zh) * 2017-03-21 2020-08-14 浙江奥翔药业股份有限公司 依利格鲁司他的合成方法及其中间体化合物
CN108822072B (zh) * 2017-04-11 2021-01-12 中国医学科学院药物研究所 一种制备伊力格鲁司他的方法
WO2018193090A2 (en) 2017-04-21 2018-10-25 Amneal Pharmaceuticals Company Gmbh Process for preparation of eliglustat hemitartrate and intermediates thereof
ZA201803719B (en) 2017-06-05 2019-04-24 Cipla Ltd Stable solid dispersions of eliglustat hemitartrate
WO2019118707A1 (en) 2017-12-15 2019-06-20 Genzyme Corporation Methods for treating gaucher disease
US12064414B2 (en) 2017-12-20 2024-08-20 Aizant Drug Research Solutions Private Limited. Stable amorphous Eliglustat premix and process for the preparation thereof
CN111217791B (zh) * 2018-11-27 2024-02-02 广东东阳光药业股份有限公司 依鲁司他中间体及其制备方法
EP3941917A4 (de) * 2019-03-22 2022-12-21 Piramal Pharma Limited Verbessertes verfahren zur herstellung von eliglustat und seinem zwischenprodukt
WO2020193746A1 (en) 2019-03-28 2020-10-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the survival of patients suffering from melanoma
JP7698320B2 (ja) 2019-10-23 2025-06-25 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガン グルコシルセラミドシンターゼ阻害剤およびそれを使用する治療方法
WO2021214771A1 (en) 2020-04-23 2021-10-28 The Israel Institute of Biological Research (IIBR) Glucosylceramide synthase inhibitors for prevention and treatment of viral diseases
WO2021221953A1 (en) 2020-04-28 2021-11-04 The Regents Of The University Of Michigan Pyridine inhibitors of glucosylceramide synthase and therapeutic methods using the same
CN116120274A (zh) 2021-11-12 2023-05-16 曙方(上海)医药科技有限公司 依利格鲁司他可药用盐及其晶型
EP4201403A1 (de) 2021-12-21 2023-06-28 Som Innovation Biotech, S.L. Verbindungen tirapazamin und quazinon zur verwendung bei der behandlung von gm2-gangliosidosen
WO2026006099A1 (en) 2024-06-24 2026-01-02 Genzyme Corporation Eliglustat for the treatment of gaucher disease

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8311286D0 (en) 1983-04-26 1983-06-02 Searle & Co Carboxyalkyl peptide derivatives
DE3522475A1 (de) 1985-06-22 1987-01-02 Kali Chemie Pharma Gmbh Neue aromatische verbindungen, ihre herstellung und verwendung
JPH0416856A (ja) 1990-05-10 1992-01-21 Canon Inc 正帯電性非磁性トナー
ZA929008B (en) 1991-12-13 1993-05-21 Bristol Myers Squibb Co Piperazinyl- and piperidinyl-cyclohexanols.
US5707649A (en) 1993-08-13 1998-01-13 Seikagaku Corporation Agent for treating neuronal diseases
ATE195944T1 (de) 1994-02-02 2000-09-15 Liposome Co Inc Pharmazeutisch wirksame verbindungen und liposome und verfahren zu deren herstellung
WO1995034530A1 (en) * 1994-06-10 1995-12-21 Seikagaku Corporation 2-acylaminopropanol compound and medicinal composition
FR2734819B1 (fr) 1995-05-31 1997-07-04 Adir Nouveaux composes de la piperazine, de la piperidine et de la 1,2,5,6-tetrahydropyridine, leur procede de preparation et les compositions pharmaceutiques les contenant
US5916911A (en) 1995-09-20 1999-06-29 The Regents Of The University Of Michigan Amino ceramide--like compounds and therapeutic methods of use
US20030073680A1 (en) 1995-09-20 2003-04-17 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
WO2001004108A1 (en) 1999-07-09 2001-01-18 Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
US6255336B1 (en) 1995-09-20 2001-07-03 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
NO965193L (no) 1995-12-08 1997-06-09 Seikagaku Kogyo Kk Seikagaku C Aminalkoholderivat og fremgangsmåte for fremstilling derav
JP3993908B2 (ja) * 1995-12-08 2007-10-17 生化学工業株式会社 アミノアルコール誘導体及び該誘導体の製造方法
JP4140984B2 (ja) 1995-12-20 2008-08-27 生化学工業株式会社 分化誘導作用を有する薬剤
US5916802A (en) * 1997-02-19 1999-06-29 Fritz Berthold Device for measuring ATP
US5972928A (en) 1997-05-21 1999-10-26 Johns Hopkins University Methods for treatment of conditions associated with lactosylceramide
JP4036500B2 (ja) 1997-05-23 2008-01-23 生化学工業株式会社 アミノアルコール誘導体及びそれを含有する医薬
JP4176170B2 (ja) 1997-06-06 2008-11-05 生化学工業株式会社 アミノアルコール誘導体を含む医薬及び異常増殖性疾患治療薬
ES2285852T3 (es) 1998-07-27 2007-11-16 Johns Hopkins University Compuestos de diamino-propanol para el tratamiento de la isquemia.
EP1384719A1 (de) 1999-07-09 2004-01-28 The Regents of The University of Michigan Inhibitoren des Glykosylzeramidsynthase-Enzyms für die Behandlung von Krebs, Sphingolipidosis und mikrobiellen Infektionen
CA2434028C (en) 2001-01-10 2010-11-09 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
US20040260099A1 (en) 2001-01-10 2004-12-23 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
US7148251B2 (en) 2001-01-10 2006-12-12 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
US20020198240A1 (en) 2001-01-10 2002-12-26 Shayman James A. Amino ceramide - like compounds and therapeutic methods of use
EP2266968B1 (de) * 2001-07-16 2013-01-09 Genzyme Corporation Synthese von UDP-Glukose: N-Acetylsphingosin Glikosyltransferase Inhibitoren
US6916802B2 (en) 2002-04-29 2005-07-12 Genzyme Corporation Amino ceramide-like compounds and therapeutic methods of use
US20060217560A1 (en) 2002-04-29 2006-09-28 Shayman James A Amino ceramide-like compounds and therapeutic methods of use
EP2032134B1 (de) * 2006-05-09 2015-06-24 Genzyme Corporation Verfahren zur behandlung von krankhafter fettleber durch hemmung der glucosphingolipid-synthese

Also Published As

Publication number Publication date
JP2005502635A (ja) 2005-01-27
IL159905A0 (en) 2004-06-20
ES2395463T3 (es) 2013-02-15
US20030050299A1 (en) 2003-03-13
PT2266968E (pt) 2013-02-25
BE2015C029I2 (de) 2021-07-19
EP2266968A2 (de) 2010-12-29
BR122015016314B8 (pt) 2021-05-25
CY2015028I2 (el) 2016-07-27
CA2453978A1 (en) 2003-01-30
CA2453978C (en) 2011-10-11
BR122015016313B1 (pt) 2019-04-16
HK1153733A1 (en) 2012-04-05
US7763738B2 (en) 2010-07-27
HK1132267A1 (en) 2010-02-19
ES2395122T3 (es) 2013-02-08
PT2067775E (pt) 2012-07-16
BR122015016313B8 (pt) 2021-05-25
EP1409467B1 (de) 2012-04-18
US20050009872A1 (en) 2005-01-13
EP2067775A1 (de) 2009-06-10
JP2005255686A (ja) 2005-09-22
US8779163B2 (en) 2014-07-15
US20070203223A1 (en) 2007-08-30
BR0211379A (pt) 2004-08-17
US20110003987A1 (en) 2011-01-06
JP2013136618A (ja) 2013-07-11
US8138353B2 (en) 2012-03-20
EP2266968B1 (de) 2013-01-09
US20080058514A1 (en) 2008-03-06
ES2399323T3 (es) 2013-03-27
US20150148534A1 (en) 2015-05-28
CY2015028I1 (el) 2016-07-27
IL193244A0 (en) 2009-02-11
WO2003008399A1 (en) 2003-01-30
US6855830B2 (en) 2005-02-15
IL159905A (en) 2009-05-04
ES2395463T4 (es) 2013-02-12
JP5038582B2 (ja) 2012-10-03
JP2017075151A (ja) 2017-04-20
LU92717I2 (fr) 2015-11-24
EP2067775B1 (de) 2012-04-25
JP2015180656A (ja) 2015-10-15
US9546161B2 (en) 2017-01-17
BRPI0211379B8 (pt) 2021-05-25
PT1409467E (pt) 2012-10-24
FR15C0036I1 (de) 2015-06-26
JP4708073B2 (ja) 2011-06-22
US7196205B2 (en) 2007-03-27
JP6182254B2 (ja) 2017-08-16
BRPI0211379B1 (pt) 2018-02-14
US20050222244A1 (en) 2005-10-06
US20210171507A1 (en) 2021-06-10
JP5227348B2 (ja) 2013-07-03
DK2266968T3 (da) 2013-04-08
EP1409467A1 (de) 2004-04-21
US20120296088A1 (en) 2012-11-22
US7265228B2 (en) 2007-09-04
US7615573B2 (en) 2009-11-10
US20190322649A1 (en) 2019-10-24
BR122015016314B1 (pt) 2019-04-16
ATE554082T1 (de) 2012-05-15
FR15C0036I2 (fr) 2016-05-27
US20170334888A1 (en) 2017-11-23
DK1409467T3 (da) 2012-07-16
DK2067775T3 (da) 2012-07-16
EP2266968A3 (de) 2011-05-18
JP2010095546A (ja) 2010-04-30

Similar Documents

Publication Publication Date Title
ATE554082T1 (de) N-acetylsphingosin glukosyltransferase inhibitor
AU2002348261A1 (en) Diastereoselective synthesis of udp-glucose : n-acylsphingosine glucosyltransferase inhibitors
SE0100902D0 (sv) Compounds
PT923554E (pt) N-benzilpiperidina e derivados tetrahidropiridina
CY1113657T1 (el) Νεα παραγωγα βενζοφαινονης ή αλατα αυτων
ES2188095T3 (es) Carboxamidas heterociclicas.
IT1292377B1 (it) Composizioni farmaceutiche a base di prostaglandine
ATE452889T1 (de) Die hiv-protease inhibierende sulfonamide
DE60014043D1 (de) Flouride von 4-substituierten piperidin-derivaten
DE69919436D1 (de) N-Acyl und N-Aroyl Aralkylamide
DE60116514D1 (de) Amlodipin-hemimaleat
DE602005010369D1 (de) 2-thiaquinolizidines als Glycosidase- und Glycosyltransferase-Inhibitoren
AR024797A1 (es) Forma cristalina iii de la n-(4-(5-dimetilaminonaftalen-1-sulfonilamino)fenil)-3-hidroxi-2,2-dimetilpropionamida
CY1113586T1 (el) Ενας αναστολεας ν-ακυλοσφιγγοσινο γλυκοζυλοτρανσφερασης
NO20042160L (no) Inhibitorer av 11-betahydroksysteroid dehydrogenase type 1
PT1286965E (pt) Compostos de piperidina e processo para a sua producao
NO20030876L (no) Fremgangsmåte for racemisering av 1-benzyl-4-(4-fluorfenyl)-3- hydroksymetyl-1,2,3,6-tetrahydropyridin for bruk som mellomprodukt i syntese avparoxetin